Volnay Therapeutics

What Volnay Therapeutics does

Volnay Therapeutics is a private biotech venture builder and drug developer focused exclusively on cell and gene therapies. The company operates a hub-and-spoke model in which it scouts for scientific breakthroughs, forms ventures around those with disruptive potential, and supports each venture with initial capital, interim leadership, and expert execution to accelerate progression toward preclinical proof-of-concept and clinical validation. By centralizing expertise, capital, and operational resources, Volnay aims to mitigate clinical risk and validate commercial potential more efficiently than single-asset biotech models.

Its therapeutic portfolio spans four proprietary modalities: Programmable Immune Reactive Cells (PIRCs) for solid tumors; a polymeric delivery platform enabling selective in situ cellular reprogramming; precision-engineered regulatory T cells (Tregs) targeting pathogenic inflammation; and engineered CAR T-cell therapies designed to selectively eliminate pathogenic T cells. These programs are supported by automated manufacturing capabilities spanning cell processing, smart bioreactors, gene delivery, and fill and finish for GMP production. End use cases are patients across oncology (solid tumors), immunology (inflammatory disease), and hematologic/immune disorders.

The business model is structured around venture creation, asset development, and eventual licensing or sale of therapeutic assets to larger pharmaceutical and biotech partners. Pricing is not publicly disclosed and is not commercially applicable at the current pre-clinical stage. The company operates internationally across the US, JP, and EU, with a leadership team that includes veterans of Takeda, Merrimack, Torque, Notch, Tidal Therapeutics, and the developers behind approved products Kymriah, Abecma, and Alofisel. Board-level representation includes Mayo Clinic, Mission Biocapital, and CU Innovations, anchoring clinical, financial, and academic channels for venture sourcing and development.

Name

Volnay Therapeutics

Website

https://volnaytx.com

Company type

Private

Operating status

Operating

Short description

Volnay Therapeutics is a private biotech venture builder that uses a hub-and-spoke model to create and advance cell and gene therapy ventures across solid tumors, inflammation, and immune disorders, with the intent of licensing assets to pharma partners.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

CAR-T & TCR-T Therapies (HLAAABAC), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

• Cell and gene therapy
• Biotech venture builder
• CAR T-cell therapy
• Regulatory T cells
• Drug delivery platform

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Venture Creation and Development: Volnay creates and builds cell and gene therapy ventures around scientific breakthroughs with disruptive potential. They provide initial capital, interim leadership, and expert execution to accelerate progress towards clinical validation. The model aggregates capital and deploys expertise across multiple ventures.
2. Therapeutic Development: Developing proprietary cell and gene therapy products including PIRC therapies for solid tumors, polymeric delivery platforms, engineered Tregs, and CAR T-cell products targeting various indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Volnay Therapeutics operates as a biotech venture builder using a hub-and-spoke model that scouts for scientific breakthroughs and forms cell and gene therapy ventures around those with disruptive, high-value potential. The company supports each venture with initial capital, interim leadership, and expert execution to accelerate and de-risk progress toward preclinical proof-of-concept and clinical validation. Its in-house pipeline includes Programmable Immune Reactive Cells (PIRCs) for solid tumors, a polymeric delivery platform for in situ cellular reprogramming, precision-engineered Tregs for pathogenic inflammation, and CAR T-cell therapies targeting pathogenic T cells.

Product overview

Volnay Therapeutics is a biotech venture builder and drug developer focused on cell and gene therapies. The company operates a hub-and-spoke model, centralizing expertise and capabilities around product development and technology innovation. Their therapeutic portfolio includes Programmable Immune Reactive Cells (PIRCs) for solid tumors, a polymeric delivery platform for in situ cellular reprograming, precision-engineered Tregs targeting pathogenic inflammation, and CAR T-cell therapies for eliminating pathogenic T cells. Multiple additional candidates are in ongoing development and diligence activities. The company supports its ventures through initial capital, interim leadership, and expert execution to progress toward preclinical proof-of-concept and clinical validation.

Differentiator

Problem solved

Functional benefit

Products and services

• Programmable Immune Reactive Cells (PIRCs)

Quantifiable outcome

• Delivered approved products including Kymriah, Abecma, and Alofisel through prior ventures and team experience
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic represented on Volnay's Board of Directors through Manu Nair, LL.M, MBA. Indicates strategic alignment with leading academic medical center for potential clinical development and partnership opportunities.
• CU InnovationsminorStrategic or Co-development PartnerCU Innovations represented as a board observer through Gali Baler, PhD. CU Innovations appears to be a university-connected innovation entity providing strategic guidance.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Volnay Therapeutics